MA38699A1 - Formulation orale pour le traitement de maladies cardiovasculaires - Google Patents

Formulation orale pour le traitement de maladies cardiovasculaires

Info

Publication number
MA38699A1
MA38699A1 MA38699A MA38699A MA38699A1 MA 38699 A1 MA38699 A1 MA 38699A1 MA 38699 A MA38699 A MA 38699A MA 38699 A MA38699 A MA 38699A MA 38699 A1 MA38699 A1 MA 38699A1
Authority
MA
Morocco
Prior art keywords
treatment
cardiovascular diseases
oral formulation
statin
acetylsalicylic acid
Prior art date
Application number
MA38699A
Other languages
English (en)
Other versions
MA38699B1 (fr
Inventor
Sanz Pablo Martin
Hurtado Javier Urbano
Original Assignee
Ferrer Int
Fundación Centro Nac De Investig Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38699(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int, Fundación Centro Nac De Investig Cardiovasculares Carlos Iii filed Critical Ferrer Int
Publication of MA38699A1 publication Critical patent/MA38699A1/fr
Publication of MA38699B1 publication Critical patent/MA38699B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique qui comprend un inhibiteur de hmg-coa réductase, en particulier une statine et l'acide acétylsalicylique d'une manière à rendre minimale l'interaction de l'acide acétylsalicylique avec la statine, pour l'utilisation dans la prévention ou le traitement de maladies cardiovasculaires.
MA38699A 2013-06-06 2014-06-05 Formulation orale pour le traitement de maladies cardiovasculaires MA38699B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170909.9A EP2810644A1 (fr) 2013-06-06 2013-06-06 Formulation orale pour le traitement de maladies cardiovasculaires
PCT/EP2014/061735 WO2014195421A1 (fr) 2013-06-06 2014-06-05 Formulation orale pour le traitement de maladies cardiovasculaires

Publications (2)

Publication Number Publication Date
MA38699A1 true MA38699A1 (fr) 2017-01-31
MA38699B1 MA38699B1 (fr) 2017-09-29

Family

ID=48569993

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38699A MA38699B1 (fr) 2013-06-06 2014-06-05 Formulation orale pour le traitement de maladies cardiovasculaires

Country Status (42)

Country Link
US (1) US10617699B2 (fr)
EP (3) EP2810644A1 (fr)
JP (1) JP6151854B2 (fr)
KR (1) KR101839665B1 (fr)
CN (2) CN104224804A (fr)
AP (1) AP2015008882A0 (fr)
AR (1) AR096350A1 (fr)
AU (1) AU2014276883B2 (fr)
BR (1) BR112015030350B1 (fr)
CA (1) CA2912350C (fr)
CL (1) CL2015003561A1 (fr)
CR (1) CR20150635A (fr)
CU (1) CU24326B1 (fr)
CY (1) CY1118766T1 (fr)
DK (1) DK2986281T3 (fr)
DO (1) DOP2015000296A (fr)
EA (1) EA028969B1 (fr)
EC (1) ECSP15050273A (fr)
ES (1) ES2620078T3 (fr)
GE (1) GEP201706743B (fr)
HK (1) HK1204562A1 (fr)
HU (1) HUE033458T2 (fr)
IL (1) IL242569B (fr)
MA (1) MA38699B1 (fr)
MD (1) MD4475C1 (fr)
MX (1) MX347801B (fr)
MY (1) MY181272A (fr)
NI (1) NI201500171A (fr)
NZ (1) NZ714707A (fr)
PE (1) PE20160051A1 (fr)
PH (1) PH12015502706B1 (fr)
PL (1) PL2986281T3 (fr)
PT (1) PT2986281T (fr)
RS (1) RS55786B1 (fr)
SA (1) SA515370243B1 (fr)
SG (1) SG11201509353QA (fr)
SI (1) SI2986281T1 (fr)
TN (1) TN2015000501A1 (fr)
TW (1) TWI630928B (fr)
UA (1) UA113806C2 (fr)
WO (1) WO2014195421A1 (fr)
ZA (1) ZA201508452B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018514523A (ja) * 2015-04-16 2018-06-07 ノバルティス アーゲー リボシクリブ錠剤
CN111135149B (zh) * 2018-11-04 2021-05-11 张家港市中医医院 一种瑞舒伐他汀钙片及其制备方法
CN110693929A (zh) * 2019-09-09 2020-01-17 安徽中医药大学 复方药物组份在治疗脑梗死恢复期中的应用
EP4299063B1 (fr) * 2022-06-30 2024-05-01 Ferrer Internacional, S.A. Capsules à avaler comprenant des comprimés d'atorvastatine présentant un profil de dissolution et une biodisponibilité adaptés

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
WO1984002131A1 (fr) 1982-11-22 1984-06-07 Sandoz Ag Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
AU732465B2 (en) * 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
CA2397832C (fr) 2000-02-10 2009-11-03 Bpsi Holdings, Inc. Compositions utilisees pour former des revetements gastro-resistants acryliques
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (fr) 2003-03-10 2004-09-23 Bayer Healthcare Ag Preparations combinees d'acide acetylsalycilique pour la prevention primaire de maladies cardiovasculaires
EP1648422A4 (fr) 2003-07-28 2007-09-19 Reddys Lab Inc Dr Traitement et prevention d'accidents cardiovasculaires
JP4680061B2 (ja) 2003-08-20 2011-05-11 塩野義製薬株式会社 新規コーティング組成物
AU2004293178B8 (en) 2003-11-26 2009-01-08 Novartis Ag Organic compounds
CA2571447A1 (fr) * 2004-06-28 2006-01-05 Howard J Smith & Associates Pty Ltd Composition et procede pour le traitement et la prevention de l'atherosclerose
US20080176947A1 (en) 2005-03-11 2008-07-24 Peter Herold Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
CN101176725A (zh) * 2006-07-14 2008-05-14 兰贝克赛实验室有限公司 辛伐他汀和阿司匹林的稳定剂型
US9095519B2 (en) * 2007-02-09 2015-08-04 Alphapharm Pty Ltd Dosage form containing two or more active pharmaceutical ingredients in different physical forms
EP2180891A4 (fr) 2007-08-13 2010-12-29 Hanall Biopharma Co Ltd Préparation combinée contenant un inhibiteur de hmg-coa reductase et aspirine et son procédé d'élaboration
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
CA2720800C (fr) * 2008-03-28 2013-07-30 Ferrer Internacional S.A. Capsule pour la prevention de maladies cardiovasculaires
CN102480954B (zh) * 2009-02-11 2015-03-18 卡帝拉药物有限公司 用于动脉粥样硬化的稳定的药物组合物
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
CA2777455A1 (fr) 2009-11-09 2011-05-12 Novadex Pharmaceuticals Ab Nouveaux composes de 1,3-oxazolidine et utilisation de ces derniers comme inhibiteurs de la renine
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN102049049A (zh) * 2010-11-27 2011-05-11 王定豪 包含阿司匹林盐和他汀类药物的药物组合物

Also Published As

Publication number Publication date
HK1204562A1 (en) 2015-11-27
DOP2015000296A (es) 2016-12-30
EA201600012A1 (ru) 2016-07-29
SA515370243B1 (ar) 2016-09-19
SG11201509353QA (en) 2015-12-30
BR112015030350A2 (pt) 2017-07-25
ES2620078T3 (es) 2017-06-27
JP2016520135A (ja) 2016-07-11
SI2986281T1 (sl) 2017-07-31
CU20150173A7 (es) 2016-06-29
EP3175849A1 (fr) 2017-06-07
CN113143888A (zh) 2021-07-23
AP2015008882A0 (en) 2015-11-30
TW201536357A (zh) 2015-10-01
JP6151854B2 (ja) 2017-06-21
KR20160014622A (ko) 2016-02-11
CR20150635A (es) 2016-06-10
EP2986281A1 (fr) 2016-02-24
EP2986281B1 (fr) 2016-12-21
CA2912350A1 (fr) 2014-12-11
MD4475C1 (ro) 2017-11-30
CY1118766T1 (el) 2017-07-12
NZ714707A (en) 2019-04-26
MY181272A (en) 2020-12-21
CL2015003561A1 (es) 2016-06-10
CN104224804A (zh) 2014-12-24
ZA201508452B (en) 2017-02-22
UA113806C2 (xx) 2017-03-10
AU2014276883A1 (en) 2015-11-26
PE20160051A1 (es) 2016-01-25
RS55786B1 (sr) 2017-07-31
MD20160001A2 (ro) 2016-05-31
DK2986281T3 (en) 2017-04-03
US10617699B2 (en) 2020-04-14
PL2986281T3 (pl) 2017-06-30
CU24326B1 (es) 2018-03-13
AR096350A1 (es) 2015-12-23
ECSP15050273A (es) 2017-07-31
TWI630928B (zh) 2018-08-01
IL242569B (en) 2018-12-31
GEP201706743B (en) 2017-09-25
PH12015502706A1 (en) 2016-03-14
MA38699B1 (fr) 2017-09-29
MD4475B1 (ro) 2017-04-30
WO2014195421A1 (fr) 2014-12-11
AU2014276883B2 (en) 2017-04-20
US20160106763A1 (en) 2016-04-21
HUE033458T2 (en) 2017-12-28
MX2015015753A (es) 2016-08-03
BR112015030350B1 (pt) 2022-11-29
PH12015502706B1 (en) 2016-03-14
TN2015000501A1 (en) 2017-04-06
MX347801B (es) 2017-05-15
KR101839665B1 (ko) 2018-03-16
PT2986281T (pt) 2017-03-29
CA2912350C (fr) 2017-04-04
EA028969B1 (ru) 2018-01-31
NI201500171A (es) 2019-05-07
EP2810644A1 (fr) 2014-12-10

Similar Documents

Publication Publication Date Title
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MX2020006957A (es) Composicion de liberacion modificada que comprende un cannabinoide.
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA38699A1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
BR112013008140A8 (pt) "compostos imidazotriazinona".
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
MA41072A1 (fr) Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
MA45450B1 (fr) Formulations d'anticorps anti-cd19
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
MA34724B1 (fr) Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA39342B2 (fr) Anticorps il -21
CO2020015124A2 (es) Anticuerpo anti-tlr7 humano
MA41809A (fr) Biotine pour le traitement de la sclérose latérale amyotrophique
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
FR3061021B1 (fr) Antagoniste specifique de tlr4 dans le traitement du myelome multiple
FR3040303B1 (fr) Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
MA34232B1 (fr) Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation
ES2524645B1 (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
MA44728A (fr) Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.